Hansa Biopharma AB (publ) / Fundamentals
Income statement
- Net revenue
€17.88M - Cost of goods sold
€5.79M - Gross profit
€12.08M - SG&A expenses
€30.10M - R&D expenses
€31.04M - EBITDA
-€41.74M - D&A
€0.00 - EBIT
-€46.29M - Interest expenses
€13.34M - EBT
-€53.87M - Tax expenses
€376.52K - Net income
-€54.25M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€2.90M - Changes in working capital
-€4.99M - Operating cash flow
-€56.34M - Capex
€57.14K - Other investing cash flow
-€57.14K - Net investing cash flow
-€57.14K - Total cash dividends paid
€0.00 - Issuance of common stock
€19.88M - Debt repayment
€0.00 - Other financing cash flow
€4.73M - Net financing cash flow
€24.61M - Foreign exchange effects
-€112.92K - Net change in cash
-€31.90M - Cash at end of period
€32.25M - Free cash flow
-€56.29M
Balance sheet
- Cash and cash equivalents
€32.25M - Cash and short-term investments
€32.25M - Total receivables
€20.16M - Inventory
€267.88K - Other current assets
€0.00 - Total current assets
€52.68M - Property, plant & equipment
€1.26M - Goodwill
€0.00 - Intangible assets
€22.25M - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€23.51M - Total assets
€76.18M - Accounts payable
€0.00 - Short-term debt
€13.61M - Other current liabilities
€24.61M - Total current liabilities
€38.40M - Long-term debt
€68.85M - Deferred tax liabilities
€12.37K - Other non-current liabilities
€9.05M - Total non-current liabilities
€77.91M - Total liabilities
€116.32M - Common stock
€0.00 - Retained earnings
€0.00 - Other equity
€0.00 - Total equity
-€40.13M - Total liabilities and shareholders' equity
€76.18M
Company information
- Market capitalization
€163.61M - Employees
138 - Enterprise Value
€2.51B
Company ratios
- Gross margin
-
67.6% Much better than peer group: -267.9% - EBITDA margin
-
-233.5% Much better than peer group: -5,532.3% - EBIT margin
-
-258.9% Much better than peer group: -6,571.2% - EBT margin
-
-301.3% Much better than peer group: -13,720.5% - Net margin
-
-303.4% Much better than peer group: -25,740.2% - ROE
-
135.2% Much better than peer group: -72.1% - ROA
-
-71.2% Worse than peer group: -58.2% - Asset turnover
-
23.5% Even with peer group: 21.2% - FCF margin
-
-315.5% Much better than peer group: -33,974.9% - FCF yield
-34.5% - Efficiency ratio
333.5% - Net sales per employee
-
€129.55K - Net income per employee
-
-€393.09K